Anthraquinones and autophagy – Three rings to rule them all?. Issue 20 (15th October 2019)

• Record Type: Journal Article
• Authors: Deitersen, Jana; El-Kashef, Dina H.; Proksch, Peter; Stork, Björn
• Is Part Of: Bioorganic & medicinal chemistry. Volume 27:Issue 20(2019)
• Publication Date: 2019-10-15
• Subjects: Anthraquinones -- Autophagy -- AKT pathway -- Emodin -- Chemotherapy-resistance; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; Chemistry, Clinical -- Periodicals; Chemistry, Organic -- Periodicals; Chimie bio-organique -- Périodiques; Chimie pharmaceutique -- Périodiques; 615.19
• DOI: 10.1016/j.bmc.2019.115042
• Languages: English
• ISSNs: 0968-0896

Abstract

Graphical abstract: Abstract: In order to overcome therapy resistance in cancer, scientists search in nature for novel lead structures for the development of improved chemotherapeutics. Anthraquinones belong to a class of tricyclic organic natural compounds with promising anti-cancer effects. Anthraquinone derivatives are rich in structural diversity, and exhibit pleiotropic properties, among which the modulation of autophagy seems promising in the context of overcoming cancer-therapy resistance. Among the most promising derivatives in this regard are emodin, aloe emodin, rhein, physcion, chrysophanol and altersolanol A. On the molecular level, these compounds target autophagy via different upstream pathways including the AKT/mTOR-axis and transcription of autophagy-related proteins. The role of autophagy is pro-survival as well as cell death-promoting, depending on derivatives and their cell type specificity. This review summarizes observed effects of anthraquinone derivatives on autophagy and discusses targeted pathways and crosstalks. A cumulative knowledge about this topic paves the way for further research on modes of action, and aids to find a therapeutic window of anthraquinones in cancer-therapy.